Course of the SARS-CoV-2 (COVID-19) infection and tolerability of the SARS-CoV-2 vaccinations in patients with epilepsies in an epilepsy outpatient clinic

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00028046

Enrollment

1200

Registered

2022-02-04

Start date

2022-02-28

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G40.2 G40.3

Interventions

Group 1: Frequency of seizures during and after the SARS-CoV-2 infection and in connection with the SARS-CoV-2 vaccination will be compared.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Age> / = 18 years in outpatient treatment in our epilepsy center between December 2021 and December 2022 - Patients with confirmed epilepsies - Either confirmed SARS-CoV-2 infection or vaccination against SARS-CoV-2

Exclusion criteria

Exclusion criteria: - Patients without a confirmed diagnosis of epilepsy and / or with psychogenic, non-epiletic seizures - A declaration of consent cannot be obtained from the patient or their legal representative

Design outcomes

Primary

Measure	Time frame
Frequency of seizures during and after the SARS-CoV-2 infection and in connection with the SARS-CoV-2 vaccination	—

Secondary

Measure	Time frame
Additional safety endpoints such as aggravation of the seizure situation or central nervous system side effects in relation to the time of the SARS-CoV-2 infection and vaccination	—

Countries

Germany

Contacts

Public ContactTassanai Intravooth

Epilepsiezentrum Kork

tintravooth@epilepsiezentrum.de00497851842272

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026